マサチューセッツ州におけるがん（全種類）の臨床試験
マサチューセッツ州内の拠点で、がん（全種類）に関する96件の研究が参加者を募集しています。
マサチューセッツ州内の都市
公式研究テキスト（英語）
Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2026/10/02更新 · NCT07059884A Study of ASP3082 in Adults With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT05382559A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- Beth Israel Deaconess Medical Center - Research, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07192471uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- Mass General Brigham, Boston
- Brigham and Women's Hospital, Boston
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/29更新 · NCT05874921A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Massachusetts General Hospital, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07578571A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07127874A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
- Investigative Site, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06881992A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Reliant Medical Group Inc, Worcester
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/09/25更新 · NCT05920356A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- Dana Farber Cancer Center ( Site 4013), Boston
被験者募集中第1/2相
1 Month – 17 Years · 全性別 · 2026/09/25更新 · NCT07630974A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Dana Farber/Harvard Cancer Center, Boston
- University of Massachusetts - UMass Chan Medical School, Worcester
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06901531Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
- Massachusetts General Hospital, Boston
被験者募集中
18歳以上 · 全性別 · 2026/09/24更新 · NCT06910969Pan Tumor Rollover Study
- Dana_Farber Cancer Institute (DFCI), Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT03899155Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
- Beth Israel Deaconess Medical Center ( Site 0107), Boston
- Dana-Farber Cancer Institute ( Site 0105), Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07405164A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- Dana-Farber Cancer Institute /ID# 279690, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07365241Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston
- University of Massachusetts Memorial Medical Center, North Worcester
被験者募集中第2/3相
全年齢 · 全性別 · 2026/09/18更新 · NCT03435796A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 3013), Boston
被験者募集中第1/2相
1 Month – 17 Years · 全性別 · 2026/09/17更新 · NCT06941272Statins to Prevent Cancer Associated Blood Clots
- Beth Isreal Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07303816Proof-of-Concept Testing of the Cardiovascular Health Equity Through Food (CHEF) Intervention in Childhood Cancer Survivors
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中
18歳以下 · 全性別 · 2026/09/16更新 · NCT06609473Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
- VA Boston Jamaica Plains Campus, West Roxbury
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT05796375ACTIVATE: AI-driven Clinical-trial Trial-Information and Viability Assessment Tool for EHRs
- Dana-Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2026/09/16更新 · NCT07232043RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Dana Farber Cancer Institute, Boston
- University of Massachusetts Chan Medical Center, Worcester
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/09/15更新 · NCT07002034(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT04996875A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Dana-Farber Cancer Institute /ID# 271846, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06953960A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT05123482A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06253871Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05386108A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Boston Medical Center, Boston
- Lahey Hospital & Medical Center, Burlington
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06119581A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
- Dana Farber Cancer Institute, Boston
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/03更新 · NCT06163534Lurbinectedin in FET-Fused Tumors
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
10歳以上 · 全性別 · 2026/09/02更新 · NCT05918640Prostate Active Surveillance Study
- Beth Israel Deaconess Medical Center/Harvard Medical School, Boston
被験者募集中観察研究
21歳以上 · 男性 · 2026/09/02更新 · NCT00756665A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital (MG), Boston
被験者募集中第1相
18歳〜99歳 · 全性別 · 2026/09/01更新 · NCT06983743A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Massachusetts General Hospital, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07075185BRIDGE-SIC Efficacy Trial
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2026/08/26更新 · NCT07735442Project: Every Child for Younger Patients With Cancer
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- 他1件
被験者募集中観察研究
25歳以下 · 全性別 · 2026/08/25更新 · NCT02402244Abatacept in Immune Checkpoint Inhibitor Myocarditis
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Boston Medical Center, Boston
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/20更新 · NCT05335928A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04104776FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05919264A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
- Beth Israel Deaconess Medical Center, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/12更新 · NCT06759649A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。